Lawsuits against Pfizer were recently certified into MDL 2502 before U.S. District Judge Richard M. Gergel in South Carolina. Plaintiffs allege that the LIPITOR® (atorvastatin calcium) warning label used medical jargon that would not be considered common knowledge and furthermore did not sufficiently warn users of a link to Type-II diabetes.
The Women’s Health Initiative (WHI) released a study in 2012 showing significant risk to post-menopausal women of developing Type-II diabetes shortly after use. As one of the most profitable and widely prescribed drugs of the last two decades, many plaintiffs are expected to come forward with claims.
Individual CRESTOR® (rosuvastatin calcium) lawsuits allege numerous injuries including Kidney Damage, Liver Damage, Rhabdomyolysis (muscle damage), Sudden Cardiac Death, and the same claim of a link between Type-II diabetes and post-menopausal women.